Seeking Alpha

Mike Havrilla's  Instablog

Mike Havrilla is an index developer, pharmacist, writer, and Co-Founder of BioMedReports.com with experience that includes online investing since August 1997 and writing for investors since April 2007 with a focus on the healthcare sector and small / micro-cap stocks. Mike holds Doctor of... More
My business:
ProActive HavRx BioFund
My blog:
BioMedReports.com FDA Calendar
My book:
ProActive HavRx Stock Indexes
  • FDA, Clinical Trial Updates: WPI, UTHR, AUXL, DNDN 0 comments
    Apr 28, 2009 08:15 PM | about stocks: WPI, NVS, UTHR, AUXL, DNDN

    Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars.

     
    The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete response rulings by the agency which require more information before an approval can be granted.
     
    Watson Pharma (NYSE:WPI) confirmed the filing of an Abbreviated New Drug Application (ANDA), with Paragraph IV litigation underway, which is seeking marketing approval of a generic version of an overactive bladder drug called Enablex (darifenacin). Novartis (NYSE:NVS) has filed a lawsuit to prevent generic competition before the patent expires, causing a stay of final FDA approval for the ANDA for a period of 30 months or court resolution (whichever occurs first). According to IMS Health data, Enablex posted U.S. sales of $220M in 2008.
     
    United Therapeutics (NASDAQ:UTHR) announced on 4/28/09 that the FDA has extended the PDUFA decision date deadline for the Companys Tyvaso (inhaled treprostinil) NDA which is pending at the agency. The new PDUFA date is 7/30/09 and UTHR anticipated the delay (which was announced in a PR in mid-March) due to the submission of additional clinical trial data to the FDA, which was considered a major amendment by the agency. The additional data was related to human factors testing to validate the instructions for using the Optineb nebulizer device which delivers the medication.
     
    Auxilium Pharma (NASDAQ:AUXL) filed a BLA in early march and today announced that a priority review request was granted for XIAFLEX (clostridial collagenase for injection) as a novel, first-in-class, orphan-designated biologic for the treatment of Dupuytren's contracture, which is a progressive condition that affects the connective tissue that lies beneath the skin in the palm, resulting in collagen deposits which impair normal hand function. The PDUFA decision date deadline for the BLA is 8/28/09.
     
    Dendreon (NASDAQ:DNDN) announced today that its experimental cancer vaccine Provenge extended the life of patients with advanced prostate cancer by a median of 4.1 months, which is one month longer than the only other treatment option Taxotere. DNDN expects to file an amendment to its existing BLA during 4Q09 and Provenge has a high likelihood for approval since the results met FDA requirements with a good safety profile and survival advantage over Taxotere.
     
    Disclosure: No positions.
    Themes: FDA, Dendreon, Provenge, Clinical Trial Stocks: WPI, NVS, UTHR, AUXL, DNDN
Back To Mike Havrilla's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Full index of posts »
Latest Followers

StockTalks

  • $MNTR.PK / Healthcare IPO Stocks for 2010: Quantum Immunologics (QI), Epinex Diagnostics / News Room websites at http://bit.ly/8i3mMN/
    1 day ago
  • $ANIK / Anika Therapeutics acquires bio-polymer, regenerative medicine company / Expects FDA decision 2H10 for Monovisc injection
    1 day ago
  • $CSIQ / Canadian Solar $5 (Nov. 2008) to $28.77 today / http://seekingalpha.com/a/29sh / ProActive Clean-Tech Index at http://bit.ly/76BhUH
    1 day ago
More »
Posts by Ticker
AAPL, ABII, ABIO, ABT, ABV, ACAD, ACCP.OB, ACOR, ACUR, ACUS, ADAM, ADLS, AET, AEZS, AFFY, AGEN, AGN, ALKS, ALNY, ALPMF.PK, ALTH, ALXA, AMAG, AMGN, AMLN, AMRN, ANPI, APPA, APPY, ARDM.OB, ARKTF.PK, ARNA, ARUXF.PK, ARYX, ATHN, AUXL, AVNR, AZN, BAX, BAYRY.PK, BCRX, BDSI, BFRM, BIIB, BIOD, BMRN, BMTI, BMY, BPAX, BSX,

Latest Comments


Most Commented
  1. BioMedReports.com Mention in BusinessWeek (7 Comments)
  2. Sequenom Splattered, EXACT Sciences on the Rise (3 Comments)
  3. Who Will Take GM's Place in the Dow? (3 Comments)
  4. 13 Extreme FDA Trades: BioMedReports.com 6/1/09 Update (3 Comments)
  5. Mentor Capital: A Stealth Cancer Immunotherapy Play (3 Comments)
Posts by Themes
allos therapeutics, ANDA, ASCO, Avastin, BIO.PA, BioAlliance, biogenerics, biomed, BioMedReports.com, biotech, BLA, Botox, cancer, cancer biotech, cancer stock, China, cholesterol, Clean Energy, Clinical Trial, Clinical Trial Calendar, Clinical Trials, clinical trials, consumer staples, Crestor, DAVANAT, defensive, Dendreon, Diabetes, Discovery Labs, dividends, Dolphin Secure, Dysport, Enablex, ETF Innovators, Extreme Trades, Facebook, FDA, fda, FDA Calendar, Feraheme, Genentech, generic, Generic Drugs, Global Pharma, GTx, Health IT, Health IT Index, healthcare, Impax Labs, Impax Pharma,
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.